CD19-CAR-T2 Cells

CD19-CAR-T2 Cells are a form of chimeric antigen receptor T cell (CAR-T) therapy specifically engineered to target the CD19 antigen, which is expressed on the surface of B cells. This therapy involves collecting T cells from a patient, genetically modifying them in the laboratory to express a CAR that recognizes CD19, and then expanding these modified cells before infusing them back into the patient. The CAR construct typically includes an antibody-derived single-chain variable fragment (scFv) for antigen recognition and intracellular signaling domains for T cell activation and persistence[2][3][7]. Upon infusion, these engineered T cells seek out and destroy malignant B cells expressing CD19. CD19-targeted CAR-T therapies have demonstrated high rates of remission in relapsed or refractory B-cell malignancies such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and various types of non-Hodgkin lymphoma[1][2][6]. The mechanism relies on direct cytotoxicity against cancerous B-cells as well as induction of long-term immune surveillance. Notably, this approach can lead to prolonged B-cell aplasia due to on-target effects[1]. The specific product "CD19-CAR-T2 Cells" appears to be an investigational or research-stage variant within this class; no commercial brand name or manufacturer is currently associated with it in public sources.

Other names

third-generation anti-CD19 CAR T-cells